Menezes Pharmaceuticals Limited - Due diligence report

A 360° intelligence report on Menezes Pharmaceuticals Limited: trust score, financial health, credit view, compliance, directors, growth and…

1996-02-16 Panjim, Goa Active Unlisted Active Compliant
Share
Connect MCP
MP Menezes Pharmaceuticals Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Menezes Pharmaceuticals Limited — 360° Intelligence Report

Generated from MCA filings & public records
95/100
Trust Score
Low Risk

Menezes Pharmaceuticals Limited is assessed as Low Risk with a Trust Score of 95/100. Menezes Pharmaceuticals Limited is an active public limited indian non-government company incorporated in 1996, operating in the Financial Services sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 14 Aug 2026 from the latest processed filings. Menezes Pharmaceuticals Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
95/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 60/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 6 satisfied (15.79 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Bank Of India6 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 2 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
MARYANN VERONICA MENEZES 01234567 Director 01/04/2018 6 yrs Approved
CHRISTINE STEPHANIE MENEZES 01234567 Director 01/04/2018 6 yrs Approved
BRENDA JULIETTE NAZARETH MENEZES 01234567 Director 01/04/2018 6 yrs Approved
Peter Mark Menezes 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2015)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2020 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Menezes Remedies Limited
Subsidiaries
1
Group entities
1
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Cosme Bio-tech Private Limited Subsidiary Company 74.00%
Menezes Remedies Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 90 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Operating for 30+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
No critical warning flags detected in the available data.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence95/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment79/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view91/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
23 Dec 2025
Director appointed
CHRISTINE STEPHANIE MENEZES (Nodal Officer)
18 Dec 2025
Director appointed
Peter Mark Menezes (Additional Director)
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
06 Jan 2017
Director ceased
ANDRE JOSE JOAO DE MENEZES
27 Sep 2016
Director ceased
LAXMIKANT HARISCHANDRA BHONSLE
22 Aug 2016
Director ceased
VISHNU GAJANAN NAGARSENKAR
28 Jan 2015
Charge satisfied
Bank Of India
29 Sep 2014
Director ceased
CHRISTINE STEPHANIE MENEZES
Director ceased
BRENDA JULIETTE NAZARETH MENEZES
30 Oct 2013
Director appointed
BRENDA JULIETTE NAZARETH MENEZES (Director)
15 Jan 2013
Director ceased
PANDHARINATH JINGU SHET TALAULIKAR
07 Mar 2008
Director ceased
ARVIND KHANDEPARKAR
25 Apr 2006
Director appointed
MARYANN VERONICA MENEZES (Director)
16 Mar 2006
Charge created
Bank Of India - 3.45 cr
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 4 financial year(s).
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
All 6 registered charge(s) stand satisfied - past borrowings repaid.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2020 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Uvb Healthcare U85191TG2015PTC101177 Hyderabad, Telangana, India
Bajrang Steelmet Trading Private Limited U27100WB2010PTC149525 Kolkata, West Bengal, India
Buymec Exports Private Limited U34300PN2002PTC016833 Pune, Maharashtra, India
A H R Overseas U51909DL2000PTC103069 Delhi, Delhi, India
Ram Ban Sales Private Limited U74899DL1992PTC048609 Delhi, Delhi, India
Sri Tirumala Venkateswara Agro Private Limited U24230TG1998PTC029174 Hyderabad, Telangana, India
Amin Manilal And Company Private Limited U01100MH1974PTC017321 Mumbai, Maharashtra, India
Intrac Tyres Private Limited U25199TG1998PTC029146 Hyderabad - 18., Telangana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Menezes Pharmaceuticals Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Menezes Pharmaceuticals Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Menezes Pharmaceuticals Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 95/100, distress signals and MSME payment-delay disclosures - know whether Menezes Pharmaceuticals Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Menezes Pharmaceuticals Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Menezes Pharmaceuticals Limited an active company?

Menezes Pharmaceuticals Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Menezes Pharmaceuticals Limited financially healthy?

Menezes Pharmaceuticals Limited has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Menezes Pharmaceuticals Limited?

Its overall Trust Score is 95/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Menezes Pharmaceuticals Limited?

The ultimate holding entity is Menezes Remedies Limited. 4 active director(s) are on record.

Does Menezes Pharmaceuticals Limited have loans or charges against its assets?

No open charges - all 6 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Menezes Pharmaceuticals Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Menezes Pharmaceuticals Limited?

Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.